Futura Takes Step Closer To Key US Patent
UK development firm's future looks more secure as it is granted notice of allowance of US continuation patent for Eroxon.
HBW Insight - February 11, 2026

Japan’s Switch Momentum Continues: EC Access Widened, Opella NSAID Approved
Japan is accelerating its tightly managed switch strategy, adding a second emergency contraceptive, expanding EC access to over 7,000 pharmacies, and approving meloxicam as a new pharmacist?dispensed analgesic.
HBW Insight - February 11, 2026

Drug Makers Confront Headwinds In 2026, But MFN Doesn’t Seem Like A Big One
Exclusivity losses and US drug pricing pressure are challenges large-cap pharma companies will need to navigate, with many forecasting modest growth in 2026.
Scrip - February 11, 2026

Drug Makers Confront Headwinds In 2026, But MFN Doesn’t Seem Like A Big One
Exclusivity losses and US drug pricing pressure are challenges large-cap pharma companies will need to navigate, with many forecasting modest growth in 2026.
Scrip - February 11, 2026

CVS To Prefer Denosumab Biosimilars, Drop Prolia From Key US Formularies
Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.
Generics Bulletin - February 11, 2026

Formycon Strikes A Keytruda Biosimilar Deal With Lotus For APAC Markets
Formycon bagged a third commercialization opportunity for its pembrolizumab candidate FYB206, with Lotus Pharmaceutical taking over rights for the APAC region.
Generics Bulletin - February 11, 2026

Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data
Following 52-week maintenance data showing sustained and deepening responses, Nektar plans to advance rezpegaldesleukin into Phase III development, targeting a 2029 BLA submission.
Scrip - February 11, 2026

Intas And Kashiv Ally On Complex Peptide
Kashiv Biosciences and Intas Pharmaceuticals have announced a licensing and supply collaboration on an undisclosed complex peptide for the European, UK and Indian markets.
Generics Bulletin - February 11, 2026

Celltrion Outlines Plan To Quadruple Biosimilar Portfolio By 2038
The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.
Generics Bulletin - February 11, 2026

Bringing Net Zero Onto The Radar For UK Healthtech Innovators
A program to help healthtech innovators comply with NHS sustainability targets without compromising their unique R&D propositions has been launched by the UK government’s healthcare research arm and the Pd-m consultancy.
Medtech Insight - February 11, 2026

Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation
Incyte’s pricing moves to broaden Opzelura’s formulary access are expected to weigh on revenue in 2026, leaving the drug’s sales outlook slightly below consensus.
Scrip - February 11, 2026

Scrip Asks... What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence
About 50 pharmaceutical industry leaders surveyed by Scrip predict 2026 will mark AI's shift from pilot programs to committed operational deployment. However, competitive advantage will depend on organizational transformation and digital infrastructure maturity, not algorithmic sophistication alone.
Scrip - February 11, 2026

Immunis Bets Longevity Medicine Needs a Business Model, Not Just Biology
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
In Vivo - February 11, 2026

India Pharma Chiefs On Driving Innovation, China’s Rise And Past Patent Tussles
Indian industry stalwarts discuss taking a leaf out of China’s book to lead in biopharma innovation, call for “greater acceptability” of indigenously developed therapies and reflect on the historical struggle for changes in India's patent laws, including an incident that jolted a prime minister.
Scrip - February 11, 2026

PDUFA Reauthorization Discussions Acknowledge OTC NDAs Eligible For Stepwise Labeling Process
In latest meeting of PDUFA reauthorization nonprescription subgroup, FDAS officials acknowledged stepwise labeling submissions “already available under current regulations but may not be widely known or consistently applied.”
HBW Insight - February 11, 2026

Coty’s New Head Unveils ‘Curation’ Strategy As Firm Withdraws FY26 Guidance
Coty interim CEO Markus Strobel, who took the helm from Sue Nabi starting Jan. 1, describes the company’s new “Coty. Curated.” growth initiative during the firm’s fiscal second quarter earnings presentation.
HBW Insight - February 11, 2026

FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter
Moderna said the refusal-to-file (RTF) letter the US FDA issued declining to review the BLA for mRNA-1010 was not in line with guidance from the agency before and after the seasonal influenza vaccine candidate’s Phase III program.
Scrip - February 11, 2026